Letrozole
Brain Neoplasms
St. Jude Children's Research HospitalSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Brain Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab InSightec | Phase 3 | BB |
MOTEXAFIN GADOLINIUM HYDRATE | Phase 3 | BB |
gw786034 National Cancer Institute (NCI) | Phase 2 | BB |
Docetaxel Providence Health & Services | Phase 2 | B |
5-ala Constantinos Hadjipanayis | Phase 2 | B |
View all 26 →
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →